About this approach
Pulsed electric field ablation uses very short, high-voltage electrical pulses to damage cell membranes and destroy a planned area of soft tissue without relying primarily on heat or freezing. Cancer programs may deliver it through a needle placed through the skin, during surgery, or through a robotic bronchoscope. It is a local treatment for selected tumors, not a whole-body cancer cure, and availability depends on the tumor, anatomy, device, clinical program, and whether treatment is routine care or research.
Where it fits: Emerging nonthermal local ablation for selected soft-tissue and lung tumors, with some uses still being evaluated in clinical studies
Where this treatment is used
The U.S. Aliya system has FDA 510(k) clearance as an electrosurgical device for soft-tissue ablation, but its clearance is not a blanket approval for every cancer, tumor location, or claimed immune effect. Centers currently describe selected use in lung, liver, gastrointestinal, metastatic, or other reachable soft-tissue lesions. Early prospective studies and active trials are assessing safety, local control, and possible immune effects.
Procedure and practical considerations
Treatment may require sedation or general anesthesia and image-guided placement of a needle or bronchoscopic catheter. Risks depend on the target and access route and may include pain, bleeding, infection, pneumothorax for lung procedures, injury to nearby structures, incomplete ablation, and the need for repeat or additional treatment. Some implanted electronic devices or other medical conditions may affect eligibility. Patients should receive a written imaging and follow-up plan and know who will manage complications. PEF cancer ablation is different from cardiac pulsed-field ablation, from histotripsy, and from NanoKnife irreversible electroporation; the device, pulse pattern, evidence, and clinical indications are not interchangeable.
Clinics reporting this approach
These clinic profiles mention this approach in their published materials. Open a profile to compare locations, services, practical details, and ways to get started.
Browse all 14 connected profilesSources
Source information checked: 2026-10-07. The links below identify the public and clinic-provided materials used for this page.
Compiled by: Cancer Clinic Finder Editorial Team
- FDA 510(k) K232420: Aliya System decision summary ↗Checked 2026-10-07
- National Cancer Institute: active phase I PEF trial for metastatic breast-cancer lesions ↗Checked 2026-10-07
- Galvanize Therapeutics: Aliya PEF system, indications and limitations ↗Checked 2026-10-07
- Roswell Park: patient guide to PEF ablation ↗Checked 2026-10-07
- Duke Health: PEF ablation for selected lung tumors ↗Checked 2026-10-07
How Cancer Clinic Finder compiles information · Suggest a factual correction